ライフサイエンスコーパス: clinical heterogeneity

1 pes of CD, which contributes to its observed clinical heterogeneity.

2 lasma cell dyscrasias that may explain their clinical heterogeneity.

3 heterogeneity in these reports may be due to clinical heterogeneity.

4 aits and pathomechanisms that translate into clinical heterogeneity.

5 erized by a marked degree of morphologic and clinical heterogeneity.

6 he different transcription factors result in clinical heterogeneity.

7 that exhibits a wide range of biological and clinical heterogeneity.

8 neoplasm in children, is remarkable for its clinical heterogeneity.

9 ion products and the biological basis of the clinical heterogeneity.

10 long periods without medication, indicating clinical heterogeneity.

11 it's marked cytological, immunological, and clinical heterogeneity.

12 ups, which does not appropriately depict the clinical heterogeneity.

13 netic condition characterized by significant clinical heterogeneity.

14 criteria based on biologic, morphologic, and clinical heterogeneity.

15 er predisposition characterized by extensive clinical heterogeneity.

16 tinct monocytic chemokine signature, despite clinical heterogeneity.

17 questions remain about its comorbidities and clinical heterogeneity.

18 ular dystrophies showing extreme genetic and clinical heterogeneity.

19 which has shown considerable etiological and clinical heterogeneity.

20 subject to a high risk of selection bias and clinical heterogeneity.

21 esults were often limited by low numbers and clinical heterogeneity.

22 ial DNA (mtDNA) mutations manifest with vast clinical heterogeneity.

23 ught to account for the disorder's prominent clinical heterogeneity.

24 cterized by a striking degree of genetic and clinical heterogeneity.

25 , and probably genes, that contribute to the clinical heterogeneity.

26 tic disease, is characterized by substantial clinical heterogeneity.

27 d diseases and because there is considerable clinical heterogeneity.

28 f biomarkers relevant to AA pathogenesis and clinical heterogeneity.

29 e a group of disorders with wide genetic and clinical heterogeneity.

30 ac disorder, exhibits remarkable genetic and clinical heterogeneity.

31 ral dementia, however, there was substantial clinical heterogeneity across the C9ORF72 mutation cohor

32 protein accounts, at least in part, for the clinical heterogeneity among FA(C) patients.

33 a group of neurodevelopmental disorders with clinical heterogeneity and a substantial polygenic compo

34 interesting and testable hypothesis for the clinical heterogeneity and differential responsiveness i

35 Because of clinical heterogeneity and experimental difficulties in

36 Neuroblastoma is remarkable for its clinical heterogeneity and is characterized by genomic a

37 are ongoing, but challenges in trial design, clinical heterogeneity and need for long-term follow-up

38 emia and can provide novel insights into the clinical heterogeneity and pathobiology of sickle cell d

39 Given their clinical heterogeneity and potential for significant mor

40 that contribute to the biological basis for clinical heterogeneity and progression of prostate cance

41 tical cellular activities that contribute to clinical heterogeneity and provide diagnostic and therap

42 iagnosis of XLP is still difficult given its clinical heterogeneity and the lack of a readily availab

43 Thus, genetic ancestry may contribute to the clinical heterogeneity and variation in disease outcomes

44 y red blood cell aplasia, macrocytic anemia, clinical heterogeneity, and increased risk of malignancy

45 of studies, variability in study designs and clinical heterogeneity, and methodological shortcomings

46 ession with better outcome, further suggests clinical heterogeneity, and possible differences in trea

47 nto SSc has been hampered by its rarity, its clinical heterogeneity, and the lack of mouse models tha

48 atures of this mouse model suggest that this clinical heterogeneity arises from a cell type-specific,

49 It forces a consideration of clinical heterogeneity as well as variation in study pro

50 features in this disorder and highlights the clinical heterogeneity both within and between families

51 In conclusion, our data confirmed AIMAH's clinical heterogeneity by identifying molecularly distin

52 the molecular level that likely reflects the clinical heterogeneity characteristic of breast carcinom

53 kaemia (CLL) is characterized by substantial clinical heterogeneity, despite relatively few genetic a

54 ions, the wealth of allelic, non-allelic and clinical heterogeneities determining the phenotypic expr

55 ews and meta-analyses, which had substantial clinical heterogeneity, differing statistical methods, a

56 nges in the cortex might explain much of the clinical heterogeneity found in HD.

57 young adult rhinitis, like asthma, exhibits clinical heterogeneity identifiable by means of cluster

58 enging, particularly in light of genetic and clinical heterogeneity in addition to the emergence of n

59 The factors driving clinical heterogeneity in Alzheimer's disease are not we

60 Clinical heterogeneity in Alzheimer's disease has been w

61 Age at onset is associated with clinical heterogeneity in bipolar disorder and aggregate

62 s have sufficiently evaluated biological and clinical heterogeneity in CLL.

63 ide the basis for a molecular explanation of clinical heterogeneity in Ewing's sarcoma.

64 Clinical heterogeneity in HbE beta-thalassemia is incomp

65 ent for using transgenic Drosophila to study clinical heterogeneity in human disease.

66 The neuronal physiological correlates of clinical heterogeneity in human essential tremor are unk

67 regarding pathogenetic mechanisms underlying clinical heterogeneity in lupus erythematosus (LE).

68 These findings help explain clinical heterogeneity in lvPPA and suggest that Abeta i

69 Clinical heterogeneity in multiple sclerosis is the rule

70 r all these disorders, there is considerable clinical heterogeneity in patients with the same mutatio

71 Clinical heterogeneity in protocols for SMBP monitoring,

72 Significant clinical heterogeneity in study populations, interventio

73 strongest association with these features of clinical heterogeneity in synucleinopathies.

74 cificity, 36%-100%) and high statistical and clinical heterogeneity in tests used, eligibility criter

75 The clinical heterogeneity in the datasets was reduced by gr

76 These studies suggest that the clinical heterogeneity in the HIT immune response may be

77 CD8+ T cell response may in part explain the clinical heterogeneity in the severity of PC pneumonia.

78 Risk of bias and clinical heterogeneity in the studies were high.

79 erns of tau aggregation, which contribute to clinical heterogeneity in these disorders.

80 onmental factors must account for the marked clinical heterogeneity in these families with an abnorma

81 GHMBP2 mutations suggests genetic as well as clinical heterogeneity in these infants.

82 tumours to find out the molecular basis for clinical heterogeneity in these tumours.

83 Because of the varying features and clinical heterogeneity inherent to this disorder, patien

84 Clinical heterogeneity is a major barrier to effective t

85 Clinical heterogeneity is associated with GRN haploinsuf

86 We hypothesized that the clinical heterogeneity is explained by genetically disti

87 To date, the clinical heterogeneity is well matched by an extensive a

88 s of current treatments and within-diagnosis clinical heterogeneity, is articulated.

89 mong sarcomas, as well as their biologic and clinical heterogeneity, is that management guidelines ar

90 d rate of disease progression, with inherent clinical heterogeneity making disease quantitation diffi

91 ts' differences in their genetic background, clinical heterogeneity may be caused by rather diverse s

92 dels identify neither the molecular basis of clinical heterogeneity, nor specific therapeutic targets

93 oproliferative neoplasms, CMML has a complex clinical heterogeneity not reflected by the mutational l

94 y of these tissues to SCO1 mutations and the clinical heterogeneity observed across SCO1 pedigrees re

95 e, and nail disease, thus deconstructing the clinical heterogeneity observed among AA patients.

96 se findings indicate a genetic basis for the clinical heterogeneity observed for this inflammatory bo

97 ight into the molecular mechanism underlying clinical heterogeneity observed in Ewing's sarcoma.

98 Overall, these results may explain the clinical heterogeneity observed in GS patients and may h

99 The molecular basis for the clinical heterogeneity observed in patients with maligna

100 leading to distinct pathologies, akin to the clinical heterogeneity observed in patients with mitocho

101 Overall, our findings explain the clinical heterogeneity observed in sialidosis and may he

102 R repertoires and provides a window into the clinical heterogeneity observed.

103 Marked clinical heterogeneity occurs even among patients carryi

104 The genetic and clinical heterogeneity of ALK-negative ALCL has not been

105 e basis for the overwhelming morphologic and clinical heterogeneity of AMR.

106 well as adaptive immune responses, with the clinical heterogeneity of asthma perhaps a result of the

107 The genetic and clinical heterogeneity of breast cancer makes the identi

108 onents make an important contribution to the clinical heterogeneity of bvFTD.

109 pathogenic mechanism with the biological and clinical heterogeneity of CLL and offers opportunities f

110 e of the molecular mechanisms to explain the clinical heterogeneity of CLL.

111 review aims to discuss the pathological and clinical heterogeneity of congenital myopathies, and the

112 on does not fully explain the biological and clinical heterogeneity of DLBCLs.

113 Clinical heterogeneity of ER(-)/PR(-) tumors suggests th

114 As part of the spectrum of clinical heterogeneity of familial TAAD, we recently des

115 with different TnT alleles suggest that the clinical heterogeneity of FHC is at least partially due

116 The clinical heterogeneity of HCC, and the lack of good diag

117 We posit that reducing the clinical heterogeneity of hiPSC-based studies, by select

118 in rat models suggesting a genetic basis for clinical heterogeneity of human essential hypertension.

119 The biologic and clinical heterogeneity of lymphomas represents the major

120 d highlight the key role of modifiers in the clinical heterogeneity of PC symptoms.

121 ions in PDSS2 and confirms the molecular and clinical heterogeneity of primary CoQ(10) deficiency.

122 In view of the significant biologic and clinical heterogeneity of prostate cancer, molecular ima

123 gnificant implications for understanding the clinical heterogeneity of RBC membrane disorders.

124 The clinical heterogeneity of schizophrenia has hindered neu

125 To explore mechanisms contributing to the clinical heterogeneity of systemic mastocytosis (SM) and

126 notable yield given the diverse genetics and clinical heterogeneity of the cerebellar ataxias.

127 state cancer biology and explain in part the clinical heterogeneity of the disease.

128 cular and biological pathways underlying the clinical heterogeneity of the disease.

129 Although the clinical heterogeneity of the included studies was high,

130 Despite the clinical heterogeneity of the schizophrenia phenotype, b

131 The clinical heterogeneity of these disorders alludes to the

132 biological understanding of the substantial clinical heterogeneity of these tumours restricts therap

133 The significant genetic and clinical heterogeneity of this condition have substantia

134 g of pathogenesis and an appreciation of the clinical heterogeneity of this disease, together with th

135 nd genetic factors contributing to the known clinical heterogeneity of this disorder.

136 minant keloid disease is consistent with the clinical heterogeneity of this scarring disorder.

137 ico-basal ganglia networks contribute to the clinical heterogeneity of this syndrome.

138 Understanding this clinical heterogeneity offers the prospects to tailor th

139 offering insights into mechanisms underlying clinical heterogeneity, pathological propagation and bas

140 Despite genetic and clinical heterogeneity, PKDs have in common defects of c

141 Clinical heterogeneity precluded primary outcome meta-an

142 rrelates of schizophrenia is the substantial clinical heterogeneity present in this disorder.

143 We conclude that, despite its clinical heterogeneity, PTC is characterized by consiste

144 logic condition characterized by significant clinical heterogeneity, ranging from malignant cancers t

145 The molecular basis for this clinical heterogeneity remains incompletely understood.

146 However, it is not known whether the clinical heterogeneity seen in the disorder is reflected

147 The dramatic molecular and clinical heterogeneity seen in this tumor has led to att

148 thic hypersomnia is a rare syndrome in which clinical heterogeneity suggests a variable or multifacto

149 mphomas (CTCLs), disorders notable for their clinical heterogeneity that can present in skin or perip

150 ase in NMDs is made challenging by the broad clinical heterogeneity that exists among many NMDs and b

151 ome (LQTS) is characterized by such striking clinical heterogeneity that, even among family members c

152 The condition is characterized by marked clinical heterogeneity, the different phenotypes/modes o

153 Characterized by extreme genetic and clinical heterogeneity, the separate groups share many c

154 strategies must account for both genetic and clinical heterogeneity to identify the genes and pathway

155 Reducing clinical heterogeneity using obesity data and improved e

156 otential molecular variation underlying this clinical heterogeneity, we profiled gene expression in 6

157 The clinical heterogeneity which has long been recognized in

158 ASD has profound etiological and clinical heterogeneity, which has impeded the identifica

159 tifactorial nature and their etiological and clinical heterogeneity will prove more resistant to refi

160 Patients with 17p- CLL exhibit clinical heterogeneity, with some patients experiencing

161 tistical approach to identify and adjust for clinical heterogeneity within ACPA(-) RA and observed in

162 Our findings exemplify clinical heterogeneity within BSS and extend the body of

163 (ACPA(-)) RA has been challenging because of clinical heterogeneity within clinical cohorts.

164 Therefore, the clinical heterogeneity within the ARMS category is assoc